COVID-19疫苗安全技术(VaST)工作组:加强大流行期间的疫苗安全监测
本文概述了CDC召集的ACIP COVID-19疫苗安全技术工作组(VaST)的组织与活动,总结了大流行期间监测疫苗安全所审查的数据,并强调了CDC、ACIP和FDA根据上市后安全数据采取的行动。VaST在2020年11月至2023年4月的29个月内定期召开会议,为未来大流行加强疫苗安全监测提供了可借鉴的模式。
要点
- VaST由独立疫苗安全专家和联邦机构代表组成,专注于COVID-19疫苗安全。
- VaST在29个月内定期开会,审查安全监测系统发现的问题及其他科学或公众关注话题。
- VaST模式可在大流行时通过引入独立非政府专家加强疫苗安全监测和公众信心。
核心结论
- VaST通过独立专家与联邦机构合作,确保及时评估疫苗安全数据,其模式可在未来大流行或公共卫生紧急事件中用于加强疫苗安全监测、提升公众信心和增加透明度。
研究设计与样本
- CDC召集的ACIP COVID-19疫苗安全技术工作组(VaST)由独立疫苗安全专家和联邦机构代表组成,于2020年11月至2023年4月期间定期召开会议,审查美国多个政府疫苗安全系统的数据。
主要发现
- 截至2023年3月,FDA对来自四家制造商的六种COVID-19疫苗发布了紧急使用授权(EUA),随后批准了其中两种疫苗。
- VaST审查的安全话题包括安全监测系统中发现的问题以及其他科学或公众关注的话题。
- VaST与ACIP COVID-19疫苗工作组密切合作,该工作组利用安全数据和VaST的评估进行获益-风险评估和COVID-19疫苗接种政策指导。
临床怎么用
- VaST为CDC的COVID-19疫苗安全监测工作提供指导,并为审查美国多个政府疫苗安全系统的数据提供论坛。
- VaST确保联邦政府外部的多元科学家和临床医生及时审查疫苗安全数据。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
During the COVID-19 pandemic, candidate COVID-19 vaccines were being developed for potential use in the United States on an unprecedented, accelerated schedule. It was anticipated that once available, under U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) or FDA approval, COVID-19 vaccines would be broadly used and potentially administered to millions of individuals in a short period of time. Intensive monitoring in the post-EUA/licensure period would be necessary for timely detection and assessment of potential safety concerns. To address this, the Centers for Disease Control and Prevention (CDC) convened an Advisory Committee on Immunization Practices (ACIP) work group focused solely on COVID-19 vaccine safety, consisting of independent vaccine safety experts and representatives from federal agencies - the ACIP COVID-19 Vaccine Safety Technical Work Group (VaST). This report provides an overview of the organization and activities of VaST, summarizes data reviewed as part of the comprehensive effort to monitor vaccine safety during the COVID-19 pandemic, and highlights selected actions taken by CDC, ACIP, and FDA in response to accumulating post-authorization safety data. VaST convened regular meetings over the course of 29 months, from November 2020 through April 2023; through March 2023 FDA issued EUAs for six COVID-19 vaccines from four different manufacturers and subsequently licensed two of these COVID-19 vaccines. The independent vaccine safety experts collaborated with federal agencies to ensure timely assessment of vaccine safety data during this time. VaST worked closely with the ACIP COVID-19 Vaccines Work Group; that work group used safety data and VaST's assessments for benefit-risk assessments and guidance for COVID-19 vaccination policy. Safety topics reviewed by VaST included those identified in safety monitoring systems and other topics of scientific or public interest. VaST provided guidance to CDC's COVID-19 vaccine safety monitoring efforts, provided a forum for review of data from several U.S. government vaccine safety systems, and assured that a diverse group of scientists and clinicians, external to the federal government, promptly reviewed vaccine safety data. In the event of a future pandemic or other biological public health emergency, the VaST model could be used to strengthen vaccine safety monitoring, enhance public confidence, and increase transparency through incorporation of independent, non-government safety experts into the monitoring process, and through strong collaboration among federal and other partners.
引用
- Markowitz LE, Hopkins RH, Broder KR, et al. COVID-19 Vaccine Safety Technical (VaST) Work Group: Enhancing vaccine safety monitoring during the pandemic. Vaccine. 2024. PMID: 38341293. doi:10.1016/j.vaccine.2023.12.059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。